MPT0B392

Cat. No.: HY-101287 Purity: ≥99.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line.

For research use only. We do not sell to patients.

MPT0B392 Chemical Structure

CAS No. : 1346169-92-3

Size	Price	Stock	Quantity
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 429	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 429	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 390	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1250	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 2000	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3300	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
Customer Review

Description

IC₅₀ & Target

microtubule, JNK, apoptosis^[1]

In Vitro

MPT0B392 (B392) (0.001-0.1 μM; 24 and 48 hours) inhibits the cell viability of HL60, MOLT-4, and CCRF-CEM cells with IC₅₀s of 0.02 μM, 0.03 μM and 0.02 μM, respectively^[1].
MPT0B392 (0.1 μM; 48 hours) induces apoptosis in HL60 cancer cells^[1].
MPT0B392 (0.1 μM for 6-48 hours; 0.01-0.1 μM for 24 and 48 hours) triggers cells arrest in the G2/M phase, followed by accumulation in subG1 phase in a concentration and time-dependent manner^[1].
MPT0B392 (0.1 μM; 48 hours) increases the phosphorylation of Bcl-2, Mcl-1S and decreases in Mcl-1L^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HL60 (acute promyelocytic leukemia), MOLT-4 (acute lymphoblastic leukemia), CCRF-CEM (acute lymphoblastic leukemia) cells
Concentration:	0.001, 0.003, 0.01, 0.03, 0.1 μM
Incubation Time:	24 and 48 hours
Result:	Inhibited the cell viability.

Apoptosis Analysis^[1]

Cell Line:	HL60 cells
Concentration:	0.1 μM
Incubation Time:	48 hours
Result:	Induced apoptosis in cancer cells.

Cell Cycle Analysis^[1]

Cell Line:	HL60 cells
Concentration:	0.1 μM or 0.01, 0.03, 0.1 μM
Incubation Time:	0.1 μM for 6-48 hours; 0.01-0.1 μM for 24 and 48 hours
Result:	Triggered cells arrest in the G2/M phase, followed by accumulation in subG1 phase in a concentration and time-dependent manner.

Western Blot Analysis^[1]

Cell Line:	HL60 cells
Concentration:	0.1 μM
Incubation Time:	48 hours
Result:	Increased the phosphorylation of Bcl-2, Mcl-1S and decreased in Mcl-1L.

In Vivo

The effects of MPT0B392 (oral gavage; 50 mg/kg or 100 mg/kg for 12 or 14 days) shows relative potent anti-leukemia activity in a vivo xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Severe combined immunodeficient (SCID) mice ^[1]
Dosage:	50 mg/kg or 100 mg/kg
Administration:	Oral gavage; 12 or 14 days
Result:	Resulted in significant tumor growth delay (83.3%) and tumor volume inhibition without loss of body weight.

Molecular Weight

404.44

Formula

C₁₉H₂₀N₂O₆S

CAS No.

1346169-92-3

Appearance

Solid

Color

Light yellow to yellow

SMILES

NC1=C2C(N=C(S(=O)(C3=CC(OC)=C(OC)C(OC)=C3)=O)C=C2)=CC=C1OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (247.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4726 mL	12.3628 mL	24.7255 mL
5 mM	0.4945 mL	2.4726 mL	4.9451 mL
10 mM	0.2473 mL	1.2363 mL	2.4726 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.18 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥99.0%

Select Batch:

Data Sheet (279 KB) SDS (251 KB)

COA (250 KB)

Handling Instructions (2659 KB)

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4726 mL	12.3628 mL	24.7255 mL	61.8139 mL
	5 mM	0.4945 mL	2.4726 mL	4.9451 mL	12.3628 mL
	10 mM	0.2473 mL	1.2363 mL	2.4726 mL	6.1814 mL
	15 mM	0.1648 mL	0.8242 mL	1.6484 mL	4.1209 mL
	20 mM	0.1236 mL	0.6181 mL	1.2363 mL	3.0907 mL
	25 mM	0.0989 mL	0.4945 mL	0.9890 mL	2.4726 mL
	30 mM	0.0824 mL	0.4121 mL	0.8242 mL	2.0605 mL
	40 mM	0.0618 mL	0.3091 mL	0.6181 mL	1.5453 mL
	50 mM	0.0495 mL	0.2473 mL	0.4945 mL	1.2363 mL
	60 mM	0.0412 mL	0.2060 mL	0.4121 mL	1.0302 mL
	80 mM	0.0309 mL	0.1545 mL	0.3091 mL	0.7727 mL
	100 mM	0.0247 mL	0.1236 mL	0.2473 mL	0.6181 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MPT0B3921346169-92-3Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MPT0B392

MPT0B392 Related Antibodies

Featured Recommendations

•Related Screening Libraries: